Skip to content Skip to footer
Meitheal Pharmaceuticals

Meitheal Pharmaceuticals Reports US FDA Approval of High-Concentration Formulation of Yusimry (Biosimilar, Humira)

Shots The US FDA has approved a citrate-free, high-concentration formulation for Yusimry as an interchangeable biosimilar to Humira (adalimumab) Yusimry, a TNF blocker, is available in low and high concentration formulations via autoinjector, with the low-concentration formulation also available as a PFS Emerge Bioscience holds the approved BLA for Yusimry, while Meitheal serves as its…

Read more